📊 TPST Key Takeaways
Is Tempest Therapeutics, Inc. (TPST) a Good Investment?
Tempest Therapeutics is in critical financial distress with near-zero revenue ($203K), catastrophic operating losses (-$27.7M), and quarterly cash burn (-$7.6M) that far exceeds available liquidity ($1.8M). The balance sheet reveals a stockholders' equity of only $822K against $9.9M in liabilities, with current ratio of 0.74x signaling imminent liquidity crisis and potential insolvency within weeks without emergency capital infusion.
Tempest Therapeutics, Inc. Key Strengths (TPST)
- Early-stage biotech structure suggests pipeline development may yield breakthrough products
- Recent insider activity (3 Form 4 filings in 90 days) indicates some management engagement
- Minimal capital expenditure indicates capital-light development model
TPST Stock Risks: Tempest Therapeutics, Inc. Investment Risks
- Cash runway estimated at 2-3 weeks based on $1.8M cash against -$7.6M quarterly burn rate
- Current ratio 0.74x with debt-to-equity 5.11x indicates acute insolvency risk and inability to meet near-term obligations
- Revenue of $203K combined with -$27.7M operating loss indicates complete lack of product commercialization or market validation
- Negative interest coverage (-37.5x) and -$7.6M operating cash flow show inability to sustain operations from business activity
- Stockholders' equity devastation ($822K) leaves zero cushion; any equity financing will severely dilute existing shareholders
Key Metrics to Watch
- Cash balance and monthly cash burn trajectory - critical survival metric
- Debt covenant compliance and refinancing status - watch for default risks
- Capital raise announcements - timing and terms will determine shareholder dilution severity
- Revenue inflection - any commercial product launch or licensing agreement
- Operating expense reduction - assessment of cost control measures
Tempest Therapeutics, Inc. (TPST) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
TPST Profit Margin, ROE & Profitability Analysis
TPST vs Healthcare Sector: How Tempest Therapeutics, Inc. Compares
How Tempest Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Tempest Therapeutics, Inc. Stock Overvalued? TPST Valuation Analysis 2026
Based on fundamental analysis, Tempest Therapeutics, Inc. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Tempest Therapeutics, Inc. Balance Sheet: TPST Debt, Cash & Liquidity
TPST Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Tempest Therapeutics, Inc.'s revenue has grown significantly by 136% over the 5-year period, indicating strong business expansion. The most recent EPS of $-19.50 indicates the company is currently unprofitable.
TPST Revenue Growth, EPS Growth & YoY Performance
TPST Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2018 | $55.0K | -$5.7M | N/A |
| Q2 2018 | $81.0K | -$7.7M | N/A |
| Q1 2018 | $63.0K | -$7.4M | N/A |
| Q3 2017 | $56.0K | -$9.3M | N/A |
| Q2 2017 | $84.0K | -$18.2M | N/A |
| Q1 2017 | $63.0K | -$14.9M | N/A |
| Q3 2016 | $75.0K | -$17.9M | N/A |
| Q2 2016 | $30.0K | -$17.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Tempest Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
TPST SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Tempest Therapeutics, Inc. (CIK: 0001544227)
📋 Recent SEC Filings
❓ Frequently Asked Questions about TPST
What is the AI rating for TPST?
Tempest Therapeutics, Inc. (TPST) has an AI grade of D with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are TPST's key strengths?
Claude: Early-stage biotech structure suggests pipeline development may yield breakthrough products. Recent insider activity (3 Form 4 filings in 90 days) indicates some management engagement.
What are the risks of investing in TPST?
Claude: Cash runway estimated at 2-3 weeks based on $1.8M cash against -$7.6M quarterly burn rate. Current ratio 0.74x with debt-to-equity 5.11x indicates acute insolvency risk and inability to meet near-term obligations.
What is TPST's revenue and growth?
Tempest Therapeutics, Inc. reported revenue of $203.0K.
Does TPST pay dividends?
Tempest Therapeutics, Inc. does not currently pay dividends.
Where can I find TPST SEC filings?
Official SEC filings for Tempest Therapeutics, Inc. (CIK: 0001544227) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is TPST's EPS?
Tempest Therapeutics, Inc. has a diluted EPS of $-2.53.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is TPST's fundamental grade?
Based on our AI fundamental analysis in June 2026, Tempest Therapeutics, Inc. has a D grade with 95% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is TPST stock overvalued or undervalued?
Valuation metrics for TPST: ROE of -3,369.3% (sector avg: 15%), net margin of -13,643.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is TPST's AI grade for 2026?
Our dual AI analysis gives Tempest Therapeutics, Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is TPST's free cash flow?
Tempest Therapeutics, Inc.'s operating cash flow is $-7.6M, with capital expenditures of $0.0. FCF margin is -3,742.9%.
How does TPST compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -13,643.3% (avg: 12%), ROE -3,369.3% (avg: 15%), current ratio 0.74 (avg: 2).
Is Tempest Therapeutics, Inc. carrying too much debt?
TPST has a debt-to-equity ratio of 5.11x, which is above the Healthcare sector average of 0.6x. Combined with a current ratio below 1, this warrants careful monitoring of the balance sheet.